>>22620994The ultimate end goal is their drug, Belapectin, getting approved for at least one of two uses: advanced liver cirrhosis, or cancer in combination with existing immunotherapy drugs such as Keytruda. Both would be big markets, but cancer is one that got me into this. Many patients get no response to Keytruda and similar, and there's studies suggesting those drugs are being blocked by galectin-3, the thing GALT's drug removes. On the liver front, GALT's recent data indicated some effectiveness on patients with extreme liver disease, where there's no previously approved treatment and the expected outcome for untreated patients is gruesome death.
However, in terms of trading, I just swing trade it. The strategy is to buy low and sort shares into small swing, medium swing, and large swing buckets, and then sell high when there's spikes. The key is to use small low risk trades to recover the cost basis, reinvest the profits, and then expand the overall position using only reinvested profits, snowballing over time. Every once in a while there's a big price spike, and those are the main targets.
A critical factor is the illiquidity of this small cap stock makes it unusable for large scale funds, so instead of getting frontrun by algos all the time, a small retailer can arbitrage the illiquid fluctuations. The secret sauce is this company is backed by its billionaire chairman, Big Dick Uihlein. The reason GALT stays in a range instead of getting diluted into oblivion by fundraising like most small biotechs is they raise funds by getting money from Dick. So you're basically investing in a billionaire's private equity project except it's publicly traded.
While I'm at it, let me shill ASTS again too. They recently had a video of a presentation to the military taken down because it alluded to classified work for the Pentagon, which is not yet officially public knowledge, and described the total market for their satellites as a potential trillion dollar business.
